Analysis of Novel Cannabis Products Labeled as Containing THC-JD.

Objective: THC-JD (tetrahydrocannabioctyl) is a semi-synthetic cannabinoid with an eight-carbon C3 side chain, present in only trace amounts in hemp, requiring synthesis for commercial use. It has been promoted as potentially 19 times more potent than Δ⁹-THC, consistent with enhanced CB1 receptor affinities for cannabinoids with 7-8 carbon C3 side chains. While one peer-reviewed report identified THC-JD (tetrahydrocannabioctyl) in Japanese online products, an anecdotal report from the U.S. suggests mislabeling. Method: To inform regulatory efforts and consumer awareness and to address these discrepancies, this study chemically analyzed five U.S. commercial cannabis vape products marketed as containing THC-JD. Results: Utilizing GC-MS analysis with a Δ⁸-THC-JD reference standard, no THC-JD was detected in any of the five commercial samples. Instead, the most prevalent compound in four of the five samples was Δ⁸-THC. Conclusions: The absence of THC-JD in these products raises critical concerns for consumer safety, regulatory compliance, and industry integrity, as consumers risk unknowingly ingesting uncharacterized or mislabeled substances. The lack of standardization in THC-JD products raises critical concerns for regulatory compliance and industry integrity. Further studies are needed to characterize THC-JD products and evaluate their potential health risk to consumers.